QQ客服 官方微博 反馈留言

	Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretrnted patients with metastatic triple-negative breast cancer
	Hu, Xichun; Zhang, Jian; Xu, Binghe; Jiang, Zefei; Ragaz, Joseph; Tong, Zhongsheng; Zhang, Qingyuan; Wang, Xiaojia; Feng, Jifeng; Pang, Danmei
刊名	INTERNATIONAL JOURNAL OF CANCER
	2014
卷号	135期号:8
关键词	apatinib VEGFR2 metastatic breast cancer triple negative
ISSN号	0020-7136
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4875400
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Hu, Xichun,Zhang, Jian,Xu, Binghe,et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretrnted patients with metastatic triple-negative breast cancer[J]. INTERNATIONAL JOURNAL OF CANCER,2014,135(8).
APA	Hu, Xichun.,Zhang, Jian.,Xu, Binghe.,Jiang, Zefei.,Ragaz, Joseph.,...&Liao, Chunmei.(2014).Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretrnted patients with metastatic triple-negative breast cancer.INTERNATIONAL JOURNAL OF CANCER,135(8).
MLA	Hu, Xichun,et al."Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretrnted patients with metastatic triple-negative breast cancer".INTERNATIONAL JOURNAL OF CANCER 135.8(2014).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。